High incidence of symptomatic methemoglobinemia (metHb) in Asian patients (pts) treated with 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) and gemcitabine (GEM) in a second-line phase II trial of metastatic non-small cell lung cancer

被引：0
|
作者：
Ma, B.
Tan, E. H.
Mok, T.
Lam, K. C.
Soo, R.
Leong, S. S.
Wang, L. Z.
Mo, F.
Chan, A. T.
Goh, B. C.
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Natl Canc Ctr, Singapore, Singapore
[3] Natl Univ Singapore Hosp, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18207
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in patients with metastatic breast cancer.
    Atieh, DM
    Modiano, M
    Shriberg, L
    Brafman, L
    Szno, M
    Vahdat, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 92S - 92S
  • [2] A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
    Brigette Ma
    Boon Cher Goh
    Eng Huat Tan
    Kwok Chi Lam
    Ross Soo
    Swan Swan Leong
    Ling Zhi Wang
    Frankie Mo
    Anthony T. C. Chan
    Benny Zee
    Tony Mok
    Investigational New Drugs, 2008, 26 : 169 - 173
  • [3] A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
    Ma, Brigette
    Goh, Boon Cher
    Tan, Eng Huat
    Lam, Kwok Chi
    Soo, Ross
    Leong, Swan Swan
    Wang, Ling Zhi
    Mo, Frankie
    Chan, Anthony T. C.
    Zee, Benny
    Mok, Tony
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 169 - 173
  • [4] A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
    Mackenzie, M. J.
    Saltman, D.
    Hirte, H.
    Low, J.
    Johnson, C.
    Pond, G.
    Moore, M. J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (06) : 553 - 558
  • [5] A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
    M. J. Mackenzie
    D. Saltman
    H. Hirte
    J. Low
    C. Johnson
    G. Pond
    M. J. Moore
    Investigational New Drugs, 2007, 25 : 553 - 558
  • [6] Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer
    Kunos, C.
    Waggoner, S. E.
    Zanotti, K. M.
    DeBernardo, R.
    Fusco, N.
    Heugel, A.
    Knazek, J.
    Adams, R.
    Radivoyevitch, T.
    Dowlati, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase II Trial
    Jang, Pil Soon
    Kang, Hyun Mo
    Lee, Jeong Eun
    Kwon, Seon Jung
    An, Jin Young
    Lee, Yun Sun
    Jeong, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (04) : 344 - 351
  • [8] Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, GV
    Selvaggi, G
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 23 - 26
  • [9] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [10] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345